Puffiness and fluid retention in the hands and feet, joint aches, wrist tingling (carpal tunnel), and blood sugar creeping up over weeks — most pronounced with MK-677 and somatropin.
These accumulate rather than strike suddenly — reassess and stop rather than pushing the dose up. Check glucose if you can.
A severe persistent headache with vision changes (possible raised intracranial pressure), or symptoms of very high blood sugar — extreme thirst, confusion, vomiting — warrant urgent care.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
A stabilised GHRH(1-44) analog bearing an N-terminal hexenoyl group that resists DPP-4 degradation. Stimulates pituitary GH release, raising IGF-1 and preferentially reducing visceral adipose tissue.
The only GHRH analog with a modern FDA approval. Phase 3 trials demonstrated visceral adipose tissue reduction in HIV-associated lipodystrophy. Studied subsequently in NAFLD in HIV populations.
FDA-approved — narrowly — for reduction of excess abdominal fat in HIV-associated lipodystrophy. Prescription-only. Approval does not extend to general body composition or anti-ageing use.
Raises IGF-1; label cautions around malignancy risk given GH-axis stimulation. Contraindicated in pregnancy and active malignancy. Injection-site reactions, arthralgia, oedema. Prohibited in sport (WADA S2).
2 mg once daily SC (Egrifta), per the phase 3 HIV-lipodystrophy trials and FDA label.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.